Expert Review of Vaccines

MEDLINE-indexed, international journal publishing rigorously peer-reviewed research in the development, application, and clinical effectiveness of new vaccines.

[Expert Review of Vaccines @ExpRevVaccines]

#ExpertReviewofVaccines is a fully #OpenAccess journal providing expert commentary on the development, application and clinical effectiveness of new #vaccines

👉 Submit here: https://t.co/F4bOLJOcNb

[Expert Review of Vaccines @ExpRevVaccines]

In China, low awareness of the herpes zoster vaccine (HZV) hinders #vaccination uptake among older adults. This study aimed to investigate HZV awareness rates and associated factors among older urban Chinese adults to inform targeted interventions.
https://t.co/Q8O5aPzps5

[Expert Review of Vaccines @ExpRevVaccines]

Public health impact of nirsevimab against acute lower respiratory infections associated with respiratory syncytial #virus among Chinese infants: a modelling study
https://t.co/AfPblBrHIP

[Expert Review of Vaccines @ExpRevVaccines]

#Pneumococcal #vaccine update:
A single dose of PCV20/PCV21 is recommended for older adults & immunocompromised individuals.
• Protection thresholds vary by serotype
• Many countries continue using PCV13/15 + PPSV23 due to cost
https://t.co/xUsIRTaBDY

[Expert Review of Vaccines @ExpRevVaccines]

New Phase 3 interim data: LYB001 recombinant protein vaccine shows strong immunogenicity & a favorable safety profile as a heterologous booster after 2–3 doses of inactivated COVID-19 vaccines in adults ≥18 years. #COVID19 #Vaccines #Immunology
https://t.co/sx6JFUGwbv

[Expert Review of Vaccines @ExpRevVaccines]

New article: Economic evaluation of childhood pneumococcal conjugate vaccination programs in Qinghai and Hainan provinces, China https://t.co/vVv3Ysu9rf

[Expert Review of Vaccines @ExpRevVaccines]

Seasonal flu still causes up to 70,000 deaths/year in the EU, hitting adults ≥65 hardest.
High-dose influenza vaccines deliver 4× more antigen and stronger, longer-lasting protection
https://t.co/yjoYZKUHrY
#Influenza #Vaccination #PublicHealth

[Expert Review of Vaccines @ExpRevVaccines]

New article: Incidence of stroke following COVID-19 vaccination: a nationwide self‑controlled risk interval study in Qatar https://t.co/M1hktecixW

[Expert Review of Vaccines @ExpRevVaccines]

New study validates the iPro-VC-Be tool for measuring vaccine confidence among healthcare workers in Nigeria 🇳🇬
Findings link trust in vaccines & government directly to uptake.

#VaccineConfidence #HCWs #PublicHealth
https://t.co/PkTT9RakzO

[Expert Review of Vaccines @ExpRevVaccines]

Children in Brazil are still receiving COVID-19 vaccines based on the original virus strain—but new variants like Omicron JN.1 escape much of this protection.
https://t.co/x3OPPLGlti
#COVIDVaccines #ChildHealth #SARSCoV2

[Expert Review of Vaccines @ExpRevVaccines]

Off-Label use of vaccines may save lives and money: lessons from the province of Quebec, Canada https://t.co/a68cjIleHX
#vaccines #publichealth #Canada

[Expert Review of Vaccines @ExpRevVaccines]

🧬 Are live-attenuated vaccines (LAVs) safe for immunocompromised patients and pregnant women?
A new systematic literature review provides the most comprehensive look to date.
https://t.co/OpySvKSV7o
#Vaccines #Immunocompromised #Pregnancy #LAV #Immunization #VaccineSafety

[Expert Review of Vaccines @ExpRevVaccines]

A 2021–2025 cohort study from a General Hospital in Southern Italy evaluates the safety and medium- to long-term protection of ecombinant Zoster Vaccine (#RZV) in high-risk patients.
#RZV #Shingles #Vaccines #PublicHealth
https://t.co/rynaV7Z1PU

[Expert Review of Vaccines @ExpRevVaccines]

📊 New insights on COVID-19 vaccination & healthcare use among adults.
A study using 2022–2023 respiratory season data examines how #COVID19 vaccination influences all-cause healthcare resource utilisation in adults living with #LongCovid in UK.
https://t.co/qwpvvEpNmv

[Expert Review of Vaccines @ExpRevVaccines]

A study combining the COM-B model with discrete choice experiments (DCEs) sheds light on how parents decide about adolescent HPV vaccination.
#HPV #Vaccination #PublicHealth #HealthPolicy #China #BehavioralScience #COMB #DCE
https://t.co/FGXx07rpaC

[Expert Review of Vaccines @ExpRevVaccines]

💉 New research from South Africa shows a single-dose primary series (1+1) for PCV10 & PCV13 is largely as effective as the standard 2+1 schedule in children at 18 months.
#Vaccines #Pneumococcal #Immunization
https://t.co/FGIENDuUdC

[Expert Review of Vaccines @ExpRevVaccines]

🌍 58M people live with chronic #HepatitisC, at risk of cirrhosis & liver cancer.
New research highlights the role of broadly neutralizing antibodies targeting #HCV E2 glycoprotein and explores innovative #vaccine strategies to overcome genetic diversity.
https://t.co/cpQAIxAoG9

[Expert Review of Vaccines @ExpRevVaccines]

New approach in #EV71 vaccine development!
Using reverse cumulative distribution curves (RCDC) researchers identified the optimal dose (640 U + adjuvant) with 93% estimated protection in infants & young children.
https://t.co/0erTMkZR7s
#VaccineResearch #Immunology

[Expert Review of Vaccines @ExpRevVaccines]

Readiness assessment for cervical cancer elimination and prevention of #human #papillomavirus (HPV)-related cancers in Europe – are we winning the RACE? https://t.co/tliGJPfFTd

[Expert Review of Vaccines @ExpRevVaccines]

A new modelling study across a cohort of 25.3M older adults from Germany shows that the bivalent RSVpreF #vaccine could prevent:
• 117,360 hospitalised RSV-LRTI cases
.100,433 ambulatory cases
• 9,298 #RSV-related deaths
https://t.co/63EV1eoi23

[Expert Review of Vaccines @ExpRevVaccines]

Immunogenicity and safety of #SARSCoV2 -recombinant protein #vaccine (CHO cell) LYB001 as a heterologous booster following two- or three-dose inactivated COVID-19 vaccine in adults aged ≥18 years. https://t.co/IXlO7SWfgP